AEYE is up +392.76% since Feb ’24 pick Unlock All Top Buy Picks
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). e are only interested in those targets that are attractively valued in historical comparison.

Analysts See Plenty of Upside for Replimune

03:19pm, Thursday, 22'nd Apr 2021
Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.
SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide ex
All down 45% or more from their 52-week highs, should you consider cutting your losses?

BOE: Global Exposure At A Discount

08:29am, Tuesday, 13'th Apr 2021
BOE: Global Exposure At A Discount
Sanofi's (SNY) acquisition of Tidal Therapeutics for $160 million is set to aid innovative mRNA-based research platform with applications in oncology, immunology and other diseases.
U.S.-listed shares of Sanofi gained 0.7% in premarket trading on Wednesday after the company said it has formed a nonprofit business unit that will provide 30 essential medicines to 40 lower-income co
PARIS, April 7, 2021 /PRNewswire/ -- In an open letter, Sanofi Chief Executive Officer Paul Hudson today outlined several key projects that the company will implement to increase the impact of its Co

Is the Market For a Flu Vaccine Disappearing?

06:20am, Sunday, 04'th Apr 2021
There are five billion reasons these companies hope it's not.

A Trio of High Earnings Return Stocks

10:58am, Friday, 02'nd Apr 2021
They are yielding twice the monthly spot rate on 20-year high-quality market corporate bonds
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.
PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment
Though Daiichi Sankyo (OTCMKTS: DSNKY) and Sanofi SA (NASDAQ: SNY) came forward to help produce other pharmas' COVID-19 shots, the companies are calling it quits on their own, separate vaccine al
Sanofi SA (NASDAQ: SNY) is dropping a major investment into its supply chain by shelling C$925 million to build a new manufacturing facility in Toronto. The new facility will be operational by 202
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE